This article is mentioned in:

Introduction

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and accounts for over 500,000 deaths/year worldwide (1). Chemotherapy is of limited value in the treatment of HCC and is often challenged by the intrinsic or acquired multidrug resistance (MDR) of cancer cells (1). Indeed, MDR has been considered a major hindrance to the successful utilization of HCC chemotherapy (2). Therefore, therapies that reduce the multidrug-resistant properties of cancer cells may provide an opportunity to enhance the efficacy of chemotherapeutic approaches for HCC.

One of the underlying mechanisms of MDR is the cellular overproduction of P-glycoprotein (P-gp), which is a product of the MDR1 gene. P-gp functions as an energy-dependent drug efflux pump that reduces intracellular concentrations of chemotherapeutic agents (2). P-gp is thought to render tumors resistant to chemotherapy through the effective elimination of these agents from the cancer cells (3). A previous study has revealed an association between increased P-gp expression and MDR in HCC (4). On the other hand, the modulation of P-gp by decreasing its expression levels or disrupting its drug-efflux activity has been shown to reverse the MDR of HCC cells (5,6). The expression of P-gp has been associated with poor prognosis in clinical studies (7). Previous studies have clearly indicated that P-gp levels are a predictive factor for tumor responsiveness to chemotherapy (7,8).

The enhancer of zeste homologue 2 (EZH2) is a histone-lysine N-methyltransferase encoded by the EZH2 gene, which is located at chromosome 7q35 and contains 20 exons and 19 introns (9,10). EZH2 belongs to the Polycomb-group (PcG) family, which forms multimeric protein complexes and is involved in maintaining the transcriptional repressive state of genes via the assembly and packaging of chromatin (9,10). As the catalytic subunit of Polycomb-repressive complex 2 (PRC2), EZH2 functions as a transcriptional repressor through the addition of 3 methyl groups to lysine 27 of histone 3, which results in the stimulation of chromatin condensation (11). The enzymatic activity of EZH2 requires the highly conserved SET domain (12). A previous study suggested that the EZH2-exerted transcription repression involves a mechanism that directly controls DNA methylation (13).

With the exception of certain stem cell types, the expression of EZH2 is barely detectable or is suppressed in normal cells (14,15). On the other hand, the dysregulated expression of EZH2 has been observed in many types of cancer, including prostate cancer (16), lymphoma (17) and hepatic cancer (18), suggesting a role in cancer malignancy and progression. In particular, EZH2 expression has been shown to be associated with the progression and aggressive biological behavior of HCC (19). Targeting the enhancer of EZH2 with lentivirus-mediated RNA interference (RNAi) has been shown to inhibit HCC cell growth, which suggests that EZH2 expression plays a role in HCC malignancies (20).

Despite its well-documented role in cancer malignancy, the involvement of EZH2 in cancer resistance to chemotherapy has not been extensively studied. Recently, it was reported that the overexpression of EZH2 contributes to the acquired cisplatin resistance in ovarian and pancreatic cancer cells (21,22). In the current study, we investigated the role of EZH2 in the MDR of HCC cells using the Bel-7402 HCC cell line and the Bel-7402-derived multidrug-resistant cell line, Bel/FU, as an MDR model.

Materials and methods

Materials

Anti-EZH2, anti-P-gp, anti-Bax, anti-caspase-3, anti-Bcl-2, anti-CDK4 and anti-cyclin D1 antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).

Cell culture

The human Chang liver cells, the HCC Bel-7402 cells and the Bel-7402-derived multidrug-resistant Bel/FU cells were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin in an incubator with 5% CO2 at 37°C. The multidrug-resistant Bel/FU cells were maintained in the medium containing 20 μg/ml of 5-fluorouracil (5-FU).

Cell survival assay

Cell survival was determined using the methyl-thiazolyl-tetrazolium (MTT) assay. Cells were plated in 96-well plates at 5×104 cells/well and treated with 5-FU (200 μg/ml) for 24, 48, 72, 96 and 120 h. After a 3-day culture, 20 μl of MTT solution (5 mg/ml; Sigma) was added to each well for 4 h of incubation. The MTT solution was then removed and 200 μl of dimethyl sulfoxide (DMSO; Sigma) were added to dissolve the crystals. Optical density was measured at a wavelength of 570 nm using an ELISA reader.

siRNA transfection

EZH2 and control siRNAs were synthesized by Shanghai GenePharma (Shanghai, China). The targeting sequence against EZH2 and that of the control was: 5′-GAC UCU GAA UGC AGU UGC UTT-3′ and 5′-AGC AAC UGC AUU CAG AGU CTT-3′, respectively. Cells were seeded in a 6-well plate and grown in serum- and antibiotic-free medium. Transfection was performed when the cells reached 60% confluence using Oligofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Cells were refreshed with regular medium 4–6 h after transfection and were subjected to the measurement of knockdown efficiency 48 h later.

RT-PCR

Total RNA was isolated with the RNAiso™ Plus kit (Takara, Japan). Total RNA (1 μg) was reverse-transcribed into first-strand cDNA using a Takara RNA PCR kit AMV Ver.3.0 (Takara Biotechnology, Dalian, China) according to the manufacturer’s instructions. The primer sequences used were as follows: human EZH2 gene forward, 5′-GCC AGA CTG GGA AGA AAT CTG-3′ and reverse, 5′-TGT GCT GGA AAA TCC AAG TCA-3′; MDR1 gene forward, 5′-CCC ATC ATT GCA ATA GCA GG-3′ and reverse, 5′-GTT CAA ACT TCT GCT CCT GA-3′; and β-actin forward, 5′-ACC CCC ACT GAA AAA GAT GA-3′ and reverse, 5′-ATC TTC AAA CCT CAT GAT G-3′, which was used as the internal control. The primers were synthesized by Invitrogen. After heating to 94°C for 2 min, the experimental reaction with a volume of 50 μl was subjected to 32 cycles of 94°C for 30 sec, 61°C for 30 sec, and 72°C for 30 sec, and the PCR products were analyzed by 1.5% gel electrophoresis.

Cell cycle analysis

The cells were collected, washed twice with ice-cold PBS, and fixed overnight with 70% cold ethanol at 4°C. Fixed cells were resuspended in a 1 ml 0.01 mg/ml propidium iodide (PI; Sigma) solution containing 0.5% Triton X-100 and 10 μg/ml RNase in the dark at 4°C for 30 min. The DNA content was analyzed by flow cytometry using a FACSCalibur (Becton-Dickinson, Franklin Lakes, NJ, USA) with CellQuest and Modfit LT3.0 software (Becton-Dickinson).

Apoptosis analysis

Cells were trypsinized, washed with cold PBS and suspended in PBS. The apoptotic cells were detected by Annexin V and PI dual labeling using the Annexin V-FITC kit (Biosea Biotechnology Co., Beijing, China) according to the manufacturer’s instructions.

Western blot analysis

Cells were washed twice with ice-cold PBS, collected and lysed using 2 ml lysis buffer, which consisted of 50 mM Tris-HCl (pH 7.5), 137 mM NaCl, 1 mM PMSF, 1% NP40, 100 mM Na3VO4, 1 mg/ml leupeptin, 10 mg/ml pepstatin, 1 g/ml aprotinin, 1 mM PMSF and 2 mM protease inhibitor cocktail. The supernatant was collected after centrifugation and cell lysates were matched for protein concentration using the bicinchoninic acid (BCA) Protein Assay kit (Pierce). Samples were loaded on a 10% SDS-PAGE gel, transferred onto nitrocellulose membranes and blocked in 5% non-fat milk overnight, followed by incubation with primary antibodies for 2 h at room temperature, and then HRP-conjugated secondary antibodies. The bands were visualized by chemiluminescence and semiquantified by densitometric analysis.

Statistical analysis

SPSS 16.0 statistical software was used for statistical analysis. Values are presented as the means ± SD. Statistical analysis was carried out using the Student’s t-test. Differences between groups were identified as statistically significant at P<0.05. The analysis of multiple groups was performed with ANOVA with an appropriate post hoc test.

Results

EZH2 expression is increased in Bel/FU cells compared to parental Bel-7402 cells

EZH2 expression was evaluated at the mRNA and protein level in the HCC parental cells (Bel-7402) and in the 5-FU-induced multidrug-resistant cells (Bel/FU). Chang liver cells were used as a non-malignant cell control. As expected, the EZH2 mRNA and protein levels were significantly increased in the malignant cell lines compared to the Chang liver cells (Fig. 1). Of note, the Bel/FU cells harbored higher levels of EZH2 compared to the parental Bel-7402 cells, implicating EZH2 in the acquired MDR of HCC cells.

Figure 1 Increased EZH2 expression in multidrug-resistant HCC cells. The (A) mRNA and (B) protein levels of EZH1 were compared in the Chang liver cells, the HCC Bel-7402 cells and the Bel-7402-derived multidrug-resistant Bel/5FU cells. (A) Representative images of RT-PCR analysis of EZH2 mRNA in the indicated cell lines. (B) Representative images of western blot analysis of EZH2 protein levels in the indicated cell lines. (C) Semi-quantification of band intensity shown in (B) using Gel-Pro Analyzer 4.0 software. Bars represent the means ± SD from 3 independent experiments. *P<0.05 vs. Bel-7402 cells.

siRNA-mediated depletion of EZH2 decreases P-gp expression in Bel/FU cells

Given the well-established function of EZH2 as a transcription repressor (23), the effect of EZH2 depletion at the mRNA expression level of the MDR1 gene was measured in the Bel/FU cells. The optimal RNAi concentration and conditions were determined by applying various doses of siRNA (Fig. 2A, left panel) and measuring the mRNA level at different time-points (Fig. 2A, right panel). EZH2 siRNA at 56 nM decreased EZH2 mRNA expression by >80%; this effect was observed at 24 h after transfection and continued for at least 72 h. The knockdown effect was confirmed by measuring the protein level (Fig. 2B).

Figure 2 siRNA-mediated depletion of EZH2 downregulates P-gp expression in multidrug-resistant HCC cells. (A) Validation of RNAi knockdown efficiency. Bel/FU cells were transfected with EZH2 siRNA at the indicated doses and the knockdown efficiency was validated by measuring the mRNA expression level using RT-PCR at the indicated time-points. (B) Western blot analysis of EZH2 protein levels at 24 h after transfection of 56 nM siRNA in Bel/FU cells. (C) RT-PCR analysis of MDR1 mRNA in Bel/FU cells transfected with control or EZH2 siRNA. (D) Western blot analysis of MDR1 mRNA in Bel/FU cells transfected with control or EZH2 siRNA; E, Semi-quantification of band intensity shown in (D) using Gel-Pro Analyzer 4.0 software. Bars represent the means ± SD from 3 independent experiments. *P<0.05 vs. control siRNA-treated cells.

By comparing the mRNA expression level of MDR1 in the cells transfected with control or EZH2 siRNA, it was found that the EZH2 depletion led to suppressed MDR1 mRNA expression (Fig. 2C) and decreased P-gp levels (Fig. 2D and E), suggesting that EZH2 is possibly involved in the transcriptional regulation of MDR1.

EZH2 siRNA reverses the resistance of Bel/FU cells to chemotherapy

The decreased expression of P-gp in the multidrug-resistant cells could possibly lead to the increased intracellular concentration of chemotherapeutic agents, thereby reversing the MDR of cancer cells. To examine this possibility, the cellular sensitivity of Bel/FU cells to 5-FU following the knockdown of EZH2 was evaluated. The cells transfected with control or EZH2 siRNA were subjected to 200 μg/ml 5-FU treatment for 24 h. The cell growth inhibitory rate (GIR) was used to indicate cell sensitivity and was calculated using the following formula: (average number of cells in the control group - average number of cells in the treated group)/average number of cells in the control group ×100 (Fig. 3). While the control siRNA-transfected Bel/FU cells barely responded to 5-FU treatment, the EZH2 siRNA-mediated depletion of EZH2 significantly increased the GIR of the Bel/FU cells, suggesting that the EZH2 knockdown which resulted in the downregulation of P-gp, may overcome the MDR of HCC cells.

Figure 3 EZH2 depletion sensitizes multidrug-resistant HCC cells to chemotherapy. (A) Representative images of cells treated with siRNA or chemotherapeutic agents. (B) Quantification of results shown in (A). The cell growth inhibitory rate was calculated using the following forumula: (average number of cells in the control group - average number of cells in the treated group)/average number of cells in the control group ×100. Bars represent the means ± SD from 3 independent experiments. *P<0.05.

EZH2 depletion inhibits the growth of Bel/FU cells

The effect of EZH2 siRNA on the basal growth rate of Bel/FU cells was then determined by MTT assay at the indicated time-points after the cells were left untreated (control), transfected with control siRNA (siControl), or transfected with EZH2 siRNA (siEZH2). The EZH2 siRNA-treated cells grew at a slower rate than the control cells, indicating that EZH2 plays a key role in the regulation of HCC cell growth (Fig. 4).

Figure 4 EZH2 siRNA suppresses the growth of multidrug-resistant HCC cells. Bel/FU cells were left untreated or treated with control or EZH2 siRNA. Cell growth was determined by MTT assay. The experiments were repeated 3 times independently.

EZH2 siRNA-treated Bel/FU cells undergo apoptosis

To investigate whether the increased apoptosis accounted for the inhibition of cell growth observed in the EZH2 siRNA-treated Bel/FU cells, the apoptotic cells were probed using Hoechst 33342 (Fig. 5A) or dual staining with PI and Annexin V (Fig. 5B). Increased numbers of apoptotic cells were detected in the EZH2 siRNA-treated cells by both methods (Fig. 5A and B). Increased apoptosis was mechanistically related to the decreased expression of the apoptosis suppressor, Bcl-2 (Fig. 5C and D), and to the activation of the pro-apoptotic protein, Bax, which is translocated from the cytosol to the mitochondria to activate mitochondria-mediated apoptosis signaling (Fig. 5E and F).

Figure 5 EZH2 siRNA enhances the apoptosis of multidrug-resistant HCC cells. Bel/FU cells were treated with control or EZH2 siRNA and apoptotic cells were detected using difference approaches. (A) Representative images of Hoechst 33342 staining. (B) Apoptotic cells were detected using Annexin V-PI dual staining. (C) Bel-2 and cleaved caspase-3 were examined using western blot analysis. (D) Band intensities shown in (C) were semi-quantified using Gel-Pro Analyzer 4.0 software and normalized with β-actin. Columns, mean of three independent experiments; bars, SD. *P<0.05 vs. control siRNA treated cells. (E) Sub-cellular Bax was examined using western blot analysis. (F) Bax in cytosol or mitochondria (Mito) shown in (E) were semi-quantified using Gel-Pro Analyzer 4.0 software and normalized with that of β-actin. Bars represent the means ± SD from 3 independent experiments. *P<0.05 vs. control siRNA-treated cells. The experiments were repeated 3 times independently.

EZH2 siRNA treatment leads to the arrest of Bel/FU cells at the G1 phase

Cell cycle progression delay represents another crucial mechanism of the inhibition of the cell growth of cancer cells (24). The effect of EZH2 siRNA on the cell cycle distribution was examined in the Bel/FU cells. FACS analysis indicated that the ratio of cells at the G1 phase was increased in the EZH2-depleted cells (65.26%) compared with the untreated (43.06%) or control siRNA-treated cells (46.45%) (Fig. 6A). Western blot analysis for key G1/S checkpoint proteins revealed that the EZH2 knockdown decreased the expression level of cyclin D1 and CDK4 (Fig. 6B and C), suggesting that the upregulated EZH2 expression in Bel/FU cells may promote cell cycle progression by modulating the expression of G1/S checkpoint regulators.

Figure 6 EZH2 siRNA arrests multidrug-resistant HCC cells at the G2/S phase. (A) Bel/FU cells were treated with control or EZH2 siRNA and cell cycle distribution was analyzed by flow cytometry. Shown are representative images of untreated (left panel), control (middle panel) or EZH2 siRNA-treated (right panel) cells. (B) Western blot analysis of samples described in (A). (C) Semi-quantification of cyclin D1 and CDK4 band intensities shown in (B) using Gel-Pro Analyzer 4.0 software. Bars represent the means ± SD from 3 independent experiments. *P<0.05 vs. control siRNA-treated cells.

Discussion

In this study, the potential of targeting the EZH2 transcription repressor in order to overcome MDR in HCC was investigated. Our results demonstrated that EZH2 expression at the mRNA and protein level was upregulated in HCC cells with acquired MDR, indicating that EZH2 possibly plays an important role in the development of MDR in HCC cells. A previous study has reported that EZH2 is overexpressed in human liver cancer cell lines and tumor tissue specimens, which appears to be associated with the promotion of tumor growth and portal vein tumor thrombus (25). Indeed, EZH2 has been proposed as a diagnostic biomarker of HCC (26). It has also been noted that EZH2 overexpression is heterogeneous and is associated with vascular infiltration, histological grade and cell proliferation activity in HCC, suggesting the role of EZH2 as a target in the treatment of advanced HCC (19).

Our findings revealed an association between MDR1 and EZH2 gene expression, as the knockdown of EZH2 decreased the MDR1 levels in HCC cells. A previous study by Grubach et al(27) demonstrated similar results in acute myeloid leukaemia. It has also been reported that the level of BMI-1, another PcG family member, correlates with the expression of MDR1 in hepatocytes (28). EZH2 and BMI-1 both belong to the PcG family and they are often co-expressed (19,29). The overexpression of MDR1 in HCC may promote the elimination of chemotherapeutic drugs, which would reduce their therapeutic effect. EZH2 silencing decreases the MDR1 mRNA and P-gp protein levels, which would lead to reduced efflux pump activity, and in turn increased sensitivity to chemotherapy in HCC cells.

While the anti-MDR effect of the EZH2 deletion is likely mediated by P-gp, the mechanism by which EZH2 regulates the proliferation of HCC cells remains unclear. In our study, we evaluated apoptosis with or without EZH2 knockdown in HCC cells and found that EZH2 siRNA significantly increased the number of cells undergoing apoptosis. A previous study by Tan et al(30) showed that EZH2 silencing in MCF-7 breast cancer cells resulted in enhanced apoptosis. The knockdown of EZH2 expression has also been observed to decrease the protein level of Bax and caspase-3 via the downregulation of E2F1 (31). Our findings are in agreement with those from previous studies, and support the concept that EZH2 overexpression may promote the proliferation of HCC cells via the prevention of apoptosis. We also observed that the EZH2 knockdown arrested multidrug-resistant HCC cells at the G1 phase, which correlated with the decrease in cyclin D1 and CDK4 levels. These results are in agreement with those from previous studies showing that RNAi-mediated EZH2 depletion led to the cell cycle arrest of colon carcinoma cells at the G1/S transition (32).

Overall, our study reveals a role of EZH2 in the MDR of HCC cells and demonstrates that the intervention of EZH2 reverses the MDR and inhibits the growth of HCC cells. The findings of this study strongly suggest that targeting EZH2 may provide a novel therapeutic approach for multidrug-resistant HCC. While the RNAi approach was used in vitro to validate the role of EZH2 in this study, the utilization of RNAi as clinical therapy requires further investigation and is technically challenging (33). The data presented in the current study may aid future studies exploring alternative approaches for modulating EZH2 function.

Acknowledgements

We thank Professor Hanfa Zou and Professor Mingliang Ye (Dalian Institute of Chemical Physics, Chinese Academy of Sciences) for their valuable assistance and critical comments on this manuscript. This study was supported by the National High Technology Research and Development Program (863 Program).

References